Oncology Data Advisor

Home
United States
Rochelle Park, NJ
Oncology Data Advisor

delivers up-to-date, clincially relevant content for the multidisciplinary care team

09/13/2025

Transitioning from oncology fellowship to an attending role is a pivotal milestone filled with challenges and rewards.

In this article, Dr. Matthew Hadfield and Dr. Alankrita Taneja reflect on their first year in independent practice, sharing insights on decision-making, mentorship, non-clinical responsibilities, and the most rewarding aspects of patient care.

Read more here: https://bit.ly/48hYiDV

08/24/2025

☀️ As we recognize Summer Sun Safety Month, Dr. Matthew Hadfield, Medical Oncologist at Brown University, shares practical guidance on UV biology, the role of sunscreens, and actionable strategies for cancer prevention.

Learn how to counsel diverse patient populations, monitor for skin cancer, and emphasize the power of prevention.

Watch the full interview: https://bit.ly/3UHVF6r

08/21/2025

The FDA has granted accelerated approval to dordaviprone (Modeyso™), the first systemic therapy for H3 K27M–mutant diffuse midline glioma.

This approval provides a critical option for adult and pediatric patients with progressive disease after prior therapy, addressing a significant unmet need.

Learn more about the clinical trials, efficacy, and safety of this groundbreaking treatment: https://bit.ly/4mBMEYl

08/15/2025

Genetic testing and counseling are transforming cancer care.

In this follow-up interview to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, Dr. Filipa Lynce and Catherine Skefos share updates on RNA testing, clinical trials like OlympiA, and strategies to improve patient outcomes.

Watch here: https://bit.ly/45Obxuj

08/14/2025

Explore the intersection of technology and cancer care in the latest edition of The Way Ahead with Dr. Waqas Haque.

Learn how cutting-edge AI is revolutionizing drug discovery, achieving up to 90% success rates in early trials, and how structured social interventions, like the CHALLENGE trial’s exercise program, are transforming patient outcomes.

Discover the balance between innovation and human oversight in healthcare: https://bit.ly/3HdfGie

08/13/2025

New Activity Alert!

Explore the latest advancements in esophagogastric cancer care in Module 1 of our new activity!

Join Dr. Yelena Y. Janjigian from Memorial Sloan Kettering Cancer Center as she discusses biomarker-guided approaches and strategies for treatment selection.

Start learning today: https://bit.ly/45606Oq

08/12/2025

The FDA’s unexpected rejection of RP1, an oncolytic virus therapy for metastatic melanoma, has sparked concern in the oncology community.

Join Dr. Matthew Hadfield and Dr. Justin Moser as they discuss the implications of this decision, the trial design controversy, and the urgent need for patient-centered regulatory processes.

Watch now to learn how this impacts patients with limited treatment options: https://bit.ly/45MOi3N

07/05/2025

The FDA has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway®) for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have progressed after EGFR-directed therapy and platinum-based chemotherapy.

This approval offers a new treatment option for patients with limited alternatives, addressing a significant unmet need.

Learn more about the TROPION-Lung trials and the clinical implications of this approval: https://bit.ly/4lI0cRV

07/01/2025

The FDA has approved mitomycin intravesical solution (Zusduri™) for adult patients with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC).

This approval offers a new non-surgical treatment option for patients with recurrent disease following TURBT, providing an alternative to repeated surgical procedures.

Learn more about the ENVISION trial results and the clinical implications of this approval: https://bit.ly/44bx53x

06/30/2025

At the 2025 ASCO Annual Meeting, Dr. Abigail Zamorano highlighted the often-overlooked distress experienced by caregivers of patients with gynecologic cancers.

Her study revealed that while patient distress remained stable during chemotherapy, caregiver distress significantly increased, with many facing challenges related to social determinants of health (SDOH).

Learn how clinicians can better support caregivers and reduce their burden: https://bit.ly/3ZOyAC3

06/29/2025

The FDA has approved pembrolizumab (Keytruda®) as a perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1.

This marks the first FDA approval for HNSCC in six years and introduces a new standard of care by integrating immunotherapy into both neoadjuvant and adjuvant settings. The KEYNOTE-689 trial demonstrated significant improvements in event-free survival (EFS), offering new hope for patients with limited perioperative options.

Learn more about this groundbreaking approval: https://bit.ly/3T9ttsq

06/28/2025

At the 2025 ASCO Annual Meeting, Dr. David Maj presented groundbreaking findings on the role of IMDC prognostic factors in metastatic renal cell carcinoma (RCC) after first-line immunotherapy.

Learn how these risk factors guide treatment decisions, inform patient counseling, and shape clinical trial design. Dr. Maj also shares messages of hope in honor of World Kidney Cancer Day on June 19.

Read more about this important research: https://bit.ly/40q21dP

Address

365 West Passaic Street, Suite 255, DPT#5036
Rochelle Park, NJ
07662

Telephone

+19739288085

Website

http://oncdata.com/

Alerts

Be the first to know and let us send you an email when Oncology Data Advisor posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Rochelle Park?